The pharmaceutical industry is experiencing an exciting transformation, shifting from transactional partnerships to strategic alliances. This shift isn’t just about adapting to market pressures – it’s ...

Now that the year is underway and a new presidential administration is in place in Washington, let’s consider the environment ...

“Companies are realizing that investing stateside can provide more control and resilience to the drug supply chain,” says Dymowski. She cites political tensions, import and export disruptions, and ...

The figure cited by Kennedy referred to the industry in which individual donors were employed. It did not refer to funds originating from, or directed by, pharmaceutical companies. On Jan. 30 ...

Royalty Pharma said its decision follows feedback from investors that the current structure made it difficult to invest in the healthcare firm, and shifting to an internal management could enhance ...

Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") today announced that the following changes to its management structure effective April 1, 2025.